

SINGAPORE
BIOTECH INVEST

21-22 March 2017

Singapore Exchange (SGX)

HONG KONG
BIOTECH INVEST

23-24 March 2017

KPMG Hong Kong

AUSTRALIA-CHINA
BIOTECH INVEST

27-28 March 2017

Shanghai Marriott Hotel City Centre

Paradigm Company Profile:

Paradigm Biopharma (PAR) listed on the ASX in August 2015. Our focus is on repurposing pentosan polysulphate sodium (PPS), an FDA approved drug that has a long track record of treating inflammation, having been used narrowly to treat bladder inflammation (interstitial cystitis) and for preventing DVT. We focus on the application of PPS in diseases sustained by inflammation, where a key feature of the activity of PPS is its anti-inflammatory and tissue regenerative properties.

We have a robust programme of clinical development, with our major clinical investigations currently focussing on the treatment of orthopaedic conditions, respiratory conditions, and the debilitating arthritis associated with arthritogenic alphaviruses (Ross River virus and chikungunya).

By working closely with the proprietary manufacturer of PPS, Paradigm Biopharma can leverage substantial knowledge and expertise available from earlier regulatory filings and accumulated toxicology safety data. With this foundation, we minimise our risk profile, and are able to accelerate the drug development cycle at significantly reduced costs.

